Get notified when TMDX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Material Weakness (worsened) — The material weakness in inventory movement controls remains, and the remediation plan has shifted from assessment to implementation, indicating the issue is still unresolved.
- Securities Litigation (worsened) — The securities class action survived a motion to dismiss and is moving into discovery, increasing litigation risk.
TransMedics Q2 revenue +20.7% to $189.9M, but net income falls 55.7% to $16.5M as costs surge
Filed August 4, 2026 · Period ending June 30, 2026 · Compared to 10-Q Jul 30, 2025 · ~1 min read
Key Changes
-
high
Operating cash flow fell 52.9% to $41.8 million in the first half of 2026 from $88.8 million a year earlier, driven by lower net income and higher working capital.
MD&A: Cash Flow verify on EDGAR → -
high
New Somerville, MA headquarters finance lease adds $347.7 million liability and $336.6 million right-of-use asset; total capital expenditures estimated at $200–240 million through 2030, with $12.7 million already committed.
Notes: Leases view on EDGAR → -
high
Securities class action survives motion to dismiss; case proceeds to discovery, increasing litigation risk.
Notes: Litigation verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (WCN 10-Q) is open in full — no account needed.
Partner
Trade TMDX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 27, 2026 · How we verify